Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 3 complete abstracts (489 words), 9 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Specialized non-fenestrated tightly-joined endothelial cells with tight junctions that form a transport barrier for certain substances between the cerebral capillaries and the brain tissue.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Barrier, Blood-Brain; Barriers, Blood-Brain; Blood Brain Barrier; Blood-Brain Barriers; Brain-Blood Barrier; Barrier, Brain-Blood; Barriers, Brain-Blood; Brain Blood Barrier.
Where it fits in the MeSH classification
- Broader topics
- Cardiovascular System; Brain
- See also
- Capillary Permeability
Related concepts
- Endothelial Cells
- Tight Junctions
- Brain
Research landscape
PubMed indexes 38,966 records tagged with the MeSH heading “Blood-Brain Barrier” (counts retrieved 2026-10-29). 11,217 of them (28.8%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 11,476 records.
Reviews account for 8,521 records (21.9%) and meta-analyses for 31. Randomized controlled trials number 102 (0.3%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 10,222 |
| 2000-2009 | 6,051 |
| 2010-2019 | 11,476 |
| 2020 onward | 11,217 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 8,521 | 21.9% |
| Meta-analyses | 31 | 0.1% |
| Randomized controlled trials | 102 | 0.3% |
Method: PubMed query "Blood-Brain Barrier"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in neuroscience
Neuroscience draws on tools with different strengths: cellular and animal work can manipulate circuits directly, while human imaging and electrophysiology observe the living brain at lower resolution. Small imaging studies are prone to false positives, and findings in animals do not always carry over to people. Clinical neurology and psychiatry rely on trials and cohort studies whose outcomes are often symptom scales. Check the species, the sample size, how the outcome was measured and whether results were replicated.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Immune-mediated blood-brain barrier disruption after ischemic stroke: mechanisms and therapeutic targets | 2025 | Review article Design not recorded in structured metadata | 17 | cc by PMID 41451205 · DOI · PMC12727575 |
| From Polyphenols to Prodrugs: Bridging the Blood-Brain Barrier with Nanomedicine and Neurotherapeutics | 2026 | Review article Design not recorded in structured metadata | 14 | cc by PMID 41828589 · DOI · PMC12985693 |
| Imaging brain inflammation and blood brain barrier permeability in neurological and psychiatric diseases: a review | 2025 | Review article Design not recorded in structured metadata | 13 | cc by PMID 41257741 · DOI · PMC12629060 |
Immune-mediated blood-brain barrier disruption after ischemic stroke: mechanisms and therapeutic targets [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Ischemic stroke is an acute cerebrovascular disorder characterized by the obstruction of cerebral arteries, leading to focal cerebral ischemia and infarction, ultimately resulting in neurological deficits.
- Closing excerpt
- This review focuses on the molecular mechanisms of ischemia and hypoxia-induced BBB dysfunction, and the immunological processes involved, aiming to provide insights into multi-target and temporally precise neuroprotective strategies for ischemic stroke.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (132 words)
Ischemic stroke is an acute cerebrovascular disorder characterized by the obstruction of cerebral arteries, leading to focal cerebral ischemia and infarction, ultimately resulting in neurological deficits. Its pathogenesis involves a cascade of immune-inflammatory responses and blood-brain barrier (BBB) disruption. Emerging evidence highlights that immune inflammation is a central driver of post-stroke brain injury. Microglial activation, neutrophil infiltration, and the release of pro-inflammatory cytokines collectively exacerbate BBB breakdown and neuronal death. Concurrently, these immune processes participate in tissue remodeling and repair. Notably, the interplay between immune-mediated inflammation and BBB damage forms a vicious cycle that aggravates neurological outcomes and hampers recovery. This review focuses on the molecular mechanisms of ischemia and hypoxia-induced BBB dysfunction, and the immunological processes involved, aiming to provide insights into multi-target and temporally precise neuroprotective strategies for ischemic stroke.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41451205 · DOI · PMC12727575
From Polyphenols to Prodrugs: Bridging the Blood-Brain Barrier with Nanomedicine and Neurotherapeutics [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Central nervous system disorders drive disability, yet many neuroactive candidates fail because the brain is a hard compartment to dose.
- Closing excerpt
- More broadly, it offers a transferable playbook for barrier-limited drug development across neurology, psychiatry, and oncology.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (210 words)
Central nervous system disorders drive disability, yet many neuroactive candidates fail because the brain is a hard compartment to dose. Plant-derived molecules spanning polyphenols, alkaloids, terpenoids, and cannabinoids are attractive because their pleiotropic actions can engage oxidative stress, neuroinflammation, and circuit dysfunction. In practice, the blood-brain barrier (BBB) restricts most native phytochemicals through tight-junction selectivity, rapid metabolism, low solubility, and transporter-mediated efflux. Key gaps include poor standardization of exposure metrics, limited human-relevant BBB models, and few head-to-head studies that compare delivery platforms on the same payload and outcome. This review tackles the mismatch between mechanistic promise and reliable brain exposure that stalls translation. The objectives are to link phytochemical liabilities to enabling strategies in nanomedicine, alternative routes, and transporter-targeted prodrugs, and to propose decision-grade endpoints for translation. We synthesize evidence on BBB transport logic, nanocarrier families, targeting ligands, intranasal delivery, focused ultrasound-mediated opening, and prodrug approaches that hijack influx transporters, while foregrounding safety and chemistry, manufacturing, and controls (CMC) constraints. Here we highlight that effective neurotherapeutics emerge when chemistry, carrier, route, and measurement are co-designed rather than optimized in isolation. This framework can guide platform selection, de-risk first in-human studies, and sharpen trial endpoints. More broadly, it offers a transferable playbook for barrier-limited drug development across neurology, psychiatry, and oncology.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41828589 · DOI · PMC12985693
Imaging brain inflammation and blood brain barrier permeability in neurological and psychiatric diseases: a review [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Neuroinflammation involving glial cell activation and BBB dysfunction has increasingly been recognized as a key feature of neuropsychiatric disorders.
- Closing excerpt
- Future methodological standardization, co-localization studies, and longitudinal multi-modal applications will be crucial for using these tools as markers of disease in the context of immune interventions in at-risk populations.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (147 words)
Neuroinflammation involving glial cell activation and BBB dysfunction has increasingly been recognized as a key feature of neuropsychiatric disorders. In vivo imaging methods, particularly translocator protein positron emission tomography (TSPO-PET) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), have advanced our understanding of glial activation and BBB permeability in conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, Huntington's disease, schizophrenia, and depression. We present key findings from the clinical application of these imaging modalities and highlight critical methodological challenges-including variability in study protocols, tracer selection, input function derivation, and parameter estimation-that currently limit cross-study comparability and clinical translation. TSPO-PET and DCE-MRI provide valuable clinical insights on the inflammatory mechanisms contributing to CNS disease at various disease stages. Future methodological standardization, co-localization studies, and longitudinal multi-modal applications will be crucial for using these tools as markers of disease in the context of immune interventions in at-risk populations.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41257741 · DOI · PMC12629060
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis [4]
- Research article Cellular and molecular mechanisms of the blood-brain barrier dysfunction in neurodegenerative diseases [5]
- Research article The blood-brain barrier: a help and a hindrance [6]
- Research article Impact of Peripheral Inflammation on Blood-Brain Barrier Dysfunction and Its Role in Neurodegenerative Diseases [7]
- Research article Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies [8]
- Research article Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis [9]
References
- Wang H, Yiqiang Z, Cai J, Guo J. Immune-mediated blood-brain barrier disruption after ischemic stroke: mechanisms and therapeutic targets. . 2025. PMID 41451205 · DOI · PMC12727575
- Tanaka M, Araujo AC, Valenti VE, Guiguer EL, Catharin VCS, Gualhardi CM, et al.. From Polyphenols to Prodrugs: Bridging the Blood-Brain Barrier with Nanomedicine and Neurotherapeutics. . 2026. PMID 41828589 · DOI · PMC12985693
- Kovbasyuk Z, Tefera E, Li C, Baete SH, Steriade C. Imaging brain inflammation and blood brain barrier permeability in neurological and psychiatric diseases: a review. . 2025. PMID 41257741 · DOI · PMC12629060
- Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis. Neurobiol Aging. 2009. PMID 17869382 · DOI
- Chen T, Dai Y, Hu C, Lin Z, Wang S, Yang J, et al.. Cellular and molecular mechanisms of the blood-brain barrier dysfunction in neurodegenerative diseases. Fluids Barriers CNS. 2024. PMID 39030617 · DOI · PMC11264766
- Rust R, Yin H, Achón Buil B, Sagare AP, Kisler K. The blood-brain barrier: a help and a hindrance. Brain. 2025. PMID 39969549 · DOI · PMC12233556
- Beltran-Velasco AI, Clemente-Suárez VJ. Impact of Peripheral Inflammation on Blood-Brain Barrier Dysfunction and Its Role in Neurodegenerative Diseases. Int J Mol Sci. 2025. PMID 40141084 · DOI · PMC11942216
- Mehdizadeh S, Mamaghani M, Hassanikia S, Pilehvar Y, Ertas YN. Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies. J Nanobiotechnology. 2025. PMID 40319325 · DOI · PMC12049023
- Ho JK, Moriarty F, Manly JJ, Larson EB, Evans DA, Rajan KB, et al.. Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis. Hypertension. 2021. PMID 34148364 · DOI · PMC9009861
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.